Wall Street is pushing back on Donald Trump’s medical claims.  

On Tuesday, shares of Kenvue, the company behind Tylenol, saw a significant rebound. This followed a day when the President sparked controversy by promoting unsubstantiated and in some instances, discredited connections between the medicine, vaccines, and autism.

Its stock rose 6 percent in pre-market trading. After the bell, the share price stabilized around $17.60, a 3.8 percent increase. 

Shares of the New Jersey consumer brands company tumbled 7.5 percent Monday following the President’s announcement.  

‘Don’t take Tylenol,’ Trump instructed pregnant women around a dozen times during the White House news conference Monday. 

He also advised mothers against giving their infants the medication, which is known as acetaminophen in the United States and paracetamol in most other countries. Additionally, he suggested that parents reconsider the current schedule for childhood vaccinations in America.

“Investors were on edge anticipating that yesterday’s statement might have serious consequences,” mentioned James Harlow, vice-president at Novare Capital Management.

‘It turned out it wasn’t, as no new scientific evidence was presented linking Tylenol to autism.’

President Trump spoke from the White House on Monday, warning pregnant women that using Tylenol might lead to autism. Wall Street is investing in the company after federal agencies didn’t cite new research in the announcement 

Despite Tuesday’s rise, Kenvue’s stock price has seen some better days. 

The drugmaker’s shares are down 18.4 percent this month, 24.4 percent in the past six months, and 17.5 percent since January 1. 

Tylenol generates roughly $1 billion in annual sales for Kenvue, according to an estimate from brokerage Morningstar.

That reliance has out the company on shaky ground with the new administration.  

Trump’s announcement comes as health secretary Robert F. Kennedy Jr., a vaccine skeptic, advances the Make America Healthy Again movement. 

He and other figures in the movement have focused on what it sees as potential causes of autism, often framing pharmaceutical companies and drugmakers as bad actors. 

Kenvue disputed any link between its products and autism this week. 

The FDA offered a more cautious look at Tylenol use for pregnant women, writing that ‘a causal relationship has not been established.’ 

Advocacy groups such as the American College of Obstetricians and Gynecologists have warned that pregnant women should take Tylenol if they’re suffering fever

Tylenol’s maker, Kenvue, has seen its stock drop this year, including hitting a record low yesterday after President Trump’s announcement 

Independent agencies, like the American College of Obstetricians and Gynecologists, said Tylenol is safe to use in moderation. 

‘Suggestions that acetaminophen use in pregnancy causes autism are not only highly concerning to clinicians but also irresponsible,’ Steven J. Fleischman, the president of the agency, said. 

‘It is highly unsettling that our federal health agencies are willing to make an announcement that will affect the health and well-being of millions of people without the backing of reliable data.’  

Kenvue also warned that if pregnant mothers don’t use Tylenol when in need, they could face a dangerous choice between suffering fevers or using riskier alternatives. 

The company was spun off from Johnson & Johnson’s pharmaceutical and medical device divisions in 2023 because it was thought that the companies could function more efficiently if they were independent from each other. 

Aside from Tylenol, the consumer health company makes Band-Aids, Listerine and other household brand names.

Citi Investment Research analyst Filippo Falorni wrote that he sees a limited risk of new lawsuits after Trump’s announcement, but thinks ‘there could be risk to Tylenol consumption given the negative headlines.’

Falorni anticipates a positive reaction for Kenvue’s stock at the opening bell on Tuesday given the lack of new scientific evidence.

The company has fought hundreds of lawsuits related to the product and its alleged ties to autism. Most have been dismissed.